DOD participated in COVID-19 antibody treatment trial
On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical…
-
-
ImmunityBio and NantKwest announced FDA authorization to study hAd5 T-cell COVID-19 vaccine
On Feb. 11, 2021, ImmunityBio and NantKwest announced they had received FDA authorization to expand Phase I testing…
-
Cue Health’s connected point-of-care Covid-19 test demonstrated 97.8% agreement compared to Central Lab PCR Testing
On Feb. 11, 2021, Cue Health announced the results of an independent clinical validation study conducted by Mayo…
-
US Government purchased additional 100 million doses of Moderna’s COVID-19 Vaccine
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
-
Rising mortality as Africa marked one year of COVID-19
On Feb. 11, 2021, the WHO announced that COVID-19 cases and deaths surged in Africa as more contagious…
-
Qatar Ministry of Public Health issued Emergency Use Authorization for COVID-19 Vaccine Moderna
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
-
Biotechnology | COVID-19 | Diagnostics | USDA | Veterinary
Oregon mink farm cleared from SARS-CoV-2; farm quarantine lifted
On Feb. 11, 2021, the Oregon Department of Agriculture (ODA) lifted the quarantine on the Oregon mink farm…
-
NIH’s TOPMed program published data on over 53,000 diverse genomes
On Feb. 10, 2021, researchers supported by the National Heart, Lung, and Blood Institute announced the publication of…
-
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
-
USDA confirmed COVID-19 in a cougar and tiger at a wild animal exhibitor in Texas
On Feb. 10, 2021, the United States Department of Agriculture (USDA) National Veterinary Services Laboratories announced confirmation of…
-
XPhyto added mescaline production to psychedelic medicine programs
On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to…
-
BioNTech updated vaccine production manufacturing site in Marburg, Germany
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
-
Relief confirmed release of preliminary findings from phase 2b/3 trial of intravenous RLF-100ﾙ (aviptadil)
On Feb. 10, 2021, RELIEF THERAPEUTICS announced the release of preliminary results from the phase 2b/3 trial of…
-
Moderna announced COVID-19 vaccine supply agreements with governments of Taiwan and Colombia
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
-
FDA authorized Eli Lilly’s monoclonal antibodies for treatment of COVID-19
On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab…
-
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
-
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
-
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
-
US COVID-19 infections nearly three times greater than reported, UTSW model estimated
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
-
Oxford Immunotec entered MOU with Green Cross to market T-SPOT Discovery SARS-CoV-2 Kit in South Korea
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
-
Repligen and Navigo Proteins announced the launch of affinity resin for the purification of COVID-19 vaccines
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they have completed the development and initiated the commercial…
-
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
-
Resurgence of Ebola reported in North Kivu in the Democratic Republic of the Congo
On Feb. 7, 2021, The Ministry of Health of the Democratic Republic of the Congo (DRC) announced that…
-
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
-
CureVac and UK Government announced collaboration on development of vaccines against SARS-CoV-2 variants
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
-
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
-
The Wellcome Sanger Institute announced sequencing 136,383 Coronavirus genomes in the UK
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
-
Oxford University vaccine effective against major B117 ‘Kent’ coronavirus strain circulating in the UK
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxford’s…
-
The US Department of Defense announced use of masks and other public health measures
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
-
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
